Menopur

Menotrophin, the active ingredient in Menopur, is a Gonadotropin (FSH/LH) preparation presented as a solution for subcutaneous injection for subcutaneous use. It treats infertility in women undergoing assisted reproduction and stimulates spermatogenesis in men with hypogonadotropic hypogonadism. GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menopur is a gonadotropin preparation used in reproductive medicine to support follicular development and spermatogenesis. - Anovulation or oligo‑ovulation: induces ovulation to enable conception. - Controlled ovarian stimulation for IVF and other assisted reproductive technologies: promotes multiple follicle development for egg retrieval. - Male hypogonadotropic hypogonadism: stimulates spermatogenesis to improve sperm production.

Menopur may cause a range of adverse reactions, most of which are related to its hormonal activity.

Common Side Effects: - Injection site pain or erythema - Abdominal discomfort or bloating - Nausea or mild vomiting - Headache - Breast tenderness - Mild ovarian hyperstimulation

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS) - Multiple pregnancy (twins or higher order) - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Allergic reaction or anaphylaxis - Ectopic pregnancy - Severe abdominal pain with rapid weight gain

When prescribing Menopur, clinicians should consider several safety measures. - Monitor ovarian response: use ultrasound and estradiol levels to adjust dosing. - Assess for hypersensitivity: discontinue if signs of allergic reaction appear. - Evaluate thromboembolic risk: avoid in patients with clotting disorders. - Use caution in patients with ovarian cysts or polycystic ovary syndrome. - Contraindicated in pregnancy: do not use in confirmed pregnancy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other hormonal agents and medications affecting coagulation.

Major Interactions (Avoid): - GnRH agonist or antagonist protocols used for IVF: may amplify ovarian response and increase OHSS risk. - High‑dose estrogen therapy: may heighten thromboembolic risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, DOACs): monitor for bleeding if OHSS occurs. - Systemic corticosteroids: may alter hormone dynamics and require dose adjustment. - Thyroid hormone replacement: assess thyroid status as gonadotropins can affect thyroid function tests.